Report #2863370

Received Oct 6, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: 50 yrs
State: —
Recovered: Unknown
Vaccinated: Sep 19, 2025
Onset: Sep 19, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	PJ353	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

Patient that received the Shingrix vaccine a Month early; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too short in a 50-year-old male patient who received Herpes zoster (Shingrix) (batch number PJ353, expiry date 31-MAR-2027) for prophylaxis. Previously administered products included Shingrix (1st dose received on 20-AUG-2025). Additional patient notes included Patient is not immunocompromised. On 19-SEP-2025, the patient received the 2nd dose of Shingrix. On 19-SEP-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too short (Verbatim: Patient that received the Shingrix vaccine a Month early). The outcome of the drug dose administration interval too short was not applicable. Additional Information: GSK Receipt Date: 19-SEP-2025 Clinical manager reported a patient received the Shingrix vaccine a month early.

Medical history

Comments: Patient is not immunocompromised